| Autor: |
M. M. Pettigrew, J. Kwon, J. F. Gent, Y. Kong, M. Wade, D. J. Williams, C. B. Creech, S. Evans, Q. Pan, E. B. Walter, J. M. Martin, J. S. Gerber, J. G. Newland, M. E. Hofto, M. A. Staat, V. G. Fowler, H. F. Chambers, W. C. Huskins |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
mBio, Vol 13, Iss 2 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2150-7511 |
| DOI: |
10.1128/mbio.00195-22 |
| Popis: |
ABSTRACT Pediatric community-acquired pneumonia (CAP) is often treated with 10 days of antibiotics. Shorter treatment strategies may be effective and lead to less resistance. The impact of duration of treatment on the respiratory microbiome is unknown. Data are from children (n = 171), ages 6 to 71 months, enrolled in the SCOUT-CAP trial (NCT02891915). Children with CAP were randomized to a short (5 days) versus standard (10 days) beta-lactam treatment strategy. Throat swabs were collected at enrollment and the end of the study and used for shotgun metagenomic sequencing. The number of beta-lactam and multidrug efflux resistance genes per prokaryotic cell (RGPC) was significantly lower in children receiving the short compared to standard treatment strategy at the end of the study (Wilcoxon rank sum test, P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
